566
Views
13
CrossRef citations to date
0
Altmetric
PHARMACOECONOMICS AND OUTCOMES IN PAIN AND PALLIATIVE CARE

A Cost-Utility Analysis of Pregabalin Versus Duloxetine for the Treatment of Painful Diabetic Neuropathy

, , &
Pages 153-164 | Received 31 Jan 2012, Accepted 14 Feb 2012, Published online: 18 Apr 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Jiejin Zhu, Wanshu Li, Changcheng Shi & Qingyu Li. (2022) A pharmacoeconomic evaluation of the pharmacotherapeutic options for painful diabetic neuropathy. Expert Opinion on Pharmacotherapy 23:5, pages 551-559.
Read now
Simone Critchlow, Matthew Hirst, Ron Akehurst, Ceri Phillips, Zoe Philips, Will Sullivan & Will C.N. Dunlop. (2017) A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future. Journal of Medical Economics 20:2, pages 129-139.
Read now
János Tajti, Délia Szok, Zsófia Majláth, Anett Csáti, Anna Petrovics-Balog & László Vécsei. (2016) Alleviation of pain in painful diabetic neuropathy. Expert Opinion on Drug Metabolism & Toxicology 12:7, pages 753-764.
Read now
Jordan B King, Marisa B Schauerhamer & Brandon K Bellows. (2015) A review of the clinical utility of duloxetine in the treatment of diabetic peripheral neuropathic pain. Therapeutics and Clinical Risk Management 11, pages 1163-1175.
Read now
Aaron I Vinik & Carolina M Casellini. (2013) Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin. Diabetes, Metabolic Syndrome and Obesity 6, pages 57-78.
Read now
Shridhar Iyer & Robert J Tanenberg. (2013) Pharmacologic management of diabetic peripheral neuropathic pain. Expert Opinion on Pharmacotherapy 14:13, pages 1765-1775.
Read now

Articles from other publishers (7)

Emma Gray, Xin Ye, Yen-Feng Wang & Shuu-Jiun Wang. (2021) Cost-Effectiveness of Mirogabalin for the Treatment of Diabetic Peripheral Neuropathic Pain in Taiwan. Value in Health Regional Issues 24, pages 148-156.
Crossref
Natalia Ruiz-Negrón, Jyothi Menon, Jordan B. King, Junjie Ma & Brandon K. Bellows. (2019) Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review. PharmacoEconomics 37:5, pages 669-688.
Crossref
Brandon K. Bellows, Richard E. Nelson, Gary M. Oderda & Joanne LaFleur. (2016) Long-term cost-effectiveness of initiating treatment for painful diabetic neuropathy with pregabalin, duloxetine, gabapentin, or desipramine. Pain 157:1, pages 203-213.
Crossref
Fernando Carlos, Luis Espejel, Diego Novick, Rubén López & Daniel Flores. (2015) Duloxetina para el tratamiento de la neuropatía diabética periférica dolorosa en Venezuela: evaluación económica. Medwave 15:08, pages e6265-e6265.
Crossref
Lindsay Parker, Rachel Huelin, Zarmina Khankhel, Radek Wasiak & Joaquin Mould. (2015) A Systematic Review of Pharmacoeconomic Studies for Pregabalin. Pain Practice 15:1, pages 82-94.
Crossref
Michael PT Lunn, Richard AC Hughes & Philip J Wiffen. (2014) Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2015:10.
Crossref
Aaron I. Vinik, Marie-Laure Nevoret, Carolina Casellini & Henri Parson. (2013) Diabetic Neuropathy. Endocrinology and Metabolism Clinics of North America 42:4, pages 747-787.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.